Back to mobile site

Alcon acquires Neurotech for $550M, adding rare eye disease drug

October 20, 2026 4:35 PM EDT Send to a Friend
Alcon (SIX/NYSE: ALC) has acquired Neurotech Pharmaceuticals, Inc. for $550 million, gaining ownership of ENCELTO, the first FDA-approved treatment for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login